Virtus Investment Advisers LLC Takes Position in Maze Therapeutics, Inc. $MAZE

Virtus Investment Advisers LLC purchased a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,940 shares of the company’s stock, valued at approximately $85,000.

A number of other institutional investors have also recently made changes to their positions in MAZE. Invesco Ltd. purchased a new position in Maze Therapeutics in the 1st quarter valued at approximately $226,000. Goldman Sachs Group Inc. purchased a new position in Maze Therapeutics in the first quarter valued at $145,000. Nuveen LLC acquired a new position in Maze Therapeutics during the 1st quarter worth $125,000. Bank of New York Mellon Corp purchased a new stake in Maze Therapeutics during the 1st quarter worth about $190,000. Finally, Octagon Capital Advisors LP acquired a new position in Maze Therapeutics during the 1st quarter worth approximately $5,153,000.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE opened at $37.75 on Monday. The stock has a fifty day moving average price of $30.51 and a 200 day moving average price of $19.98. Maze Therapeutics, Inc. has a 1-year low of $6.71 and a 1-year high of $38.85. The company has a market cap of $1.82 billion and a PE ratio of -1.81.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Wall Street Analyst Weigh In

MAZE has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Maze Therapeutics in a report on Thursday, September 18th. Raymond James Financial initiated coverage on shares of Maze Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price for the company. Guggenheim lifted their price target on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and a consensus target price of $38.57.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.